Treatment of Portal Hypertension with Acute Variceal Hemorrhage in a Patient with Cirrhosis
Clinical Scenario
Acute variceal hemorrhage occurring in a patient with liver cirrhosis — a life-threatening acute decompensating event associated with significant mortality at six weeks.
Clinical Goal
Control of variceal hemorrhage, with treatment success evaluated using five-day treatment failure as the primary endpoint.
Management Approach (Partial Overview)
Initial management involves a restrictive transfusion strategy, early antibiotic prophylaxis, and prompt initiation of vasoactive therapy — the complete sequenced regimen, parameters, and decision points are in the full protocol.
Full regimen details, sequencing, and clinical thresholds are available in the structured protocol.
References
DOI: 10.1016/j.jceh.2022.03.002
- Variceal hemorrhage, mainly from esophageal or gastric varices, is a life-threatening acute decompensating event associated with 10%–20% mortality at six weeks.
- Unique to the management of variceal bleeding in cirrhosis is thus a cautious, restrictive transfusion strategy of 7–9 gm/dL, which is associated with improved survival.
- The early initiation of vasoactive peptides (before endoscopy) is associated with improved outcomes in variceal hemorrhage.
- Somatostatin, octreotide, and terlipressin are comparable in efficacy and safety in the control of variceal hemorrhage defined by five-day treatment failure.
View source ↗